ArticleJournal of managed care & specialty pharmacy2025

First-line cyclin-dependent kinase 4 and 6 inhibitors in combination with an aromatase inhibitor for HR+/HER2- metastatic breast cancer: A real-world cost-effectiveness assessment in a US Medicare-eligible population.

Lucille Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.